169 related articles for article (PubMed ID: 33263441)
21. New developments in extracutaneous lymphomas.
Chott A; Raderer M
Semin Cutan Med Surg; 2000 Jun; 19(2):149-56. PubMed ID: 10892718
[TBL] [Abstract][Full Text] [Related]
22. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
23. Emerging treatment options for B-cell lymphomas.
Zelenetz AD
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):666-9. PubMed ID: 25995425
[TBL] [Abstract][Full Text] [Related]
24. Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.
Gaidano G; Carbone A; Pastore C; Capello D; Migliazza A; Gloghini A; Roncella S; Ferrarini M; Saglio G; Dalla-Favera R
Blood; 1997 May; 89(10):3755-62. PubMed ID: 9160681
[TBL] [Abstract][Full Text] [Related]
25. Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Naushad H; Bi C; Yu J; Bouska A; Rohr J; Chao W; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):73-88. PubMed ID: 26432520
[TBL] [Abstract][Full Text] [Related]
26. Current targeted therapies in lymphomas.
Chung C
Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
[TBL] [Abstract][Full Text] [Related]
27. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
28. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.
de Jong D; Balagué Ponz O
J Pathol; 2011 Jan; 223(2):274-82. PubMed ID: 21125680
[TBL] [Abstract][Full Text] [Related]
29. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
30. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
31. Treating lymphoma is now a bit EZ-er.
Morin RD; Arthur SE; Assouline S
Blood Adv; 2021 Apr; 5(8):2256-2263. PubMed ID: 33904892
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
Huang J; Fairbrother W; Reed JC
Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
[TBL] [Abstract][Full Text] [Related]
34. BCL6 as a therapeutic target for lymphoma.
Leeman-Neill RJ; Bhagat G
Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
[TBL] [Abstract][Full Text] [Related]
35. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
36. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
37. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences.
Otsuki T; Yano T; Clark HM; Bastard C; Kerckaert JP; Jaffe ES; Raffeld M
Blood; 1995 May; 85(10):2877-84. PubMed ID: 7742550
[TBL] [Abstract][Full Text] [Related]
38. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
39. The many layers of epigenetic dysfunction in B-cell lymphomas.
Jiang Y; Dominguez PM; Melnick AM
Curr Opin Hematol; 2016 Jul; 23(4):377-84. PubMed ID: 27055146
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]